Letters to the Editor

Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.

Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Dept. of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;
Department of Tissue Regeneration, Tokushima University Graduate School, Japan;
The University of Tokushima Graduate School of Oral Science, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Div of Transfusion Medicine & Cell Therapy, Tokushima University Hospital, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
The University of Tokushima Graduate School of Oral Science, Tokushima, Japan;
RIKEN Center for Sustainable Resource Science, Chemical Biology Research Group, Saitama, Japan;
RIKEN Center for Sustainable Resource Science, Chemical Biology Research Group, Saitama, Japan;
Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan;
Haematologica Early view Jun 25, 2020 https://doi.org/10.3324/haematol.2019.244418